ArticleNPJ precision oncology2026
AI-guided discovery of the IRF4-PAICS-LDHA axis as a multitarget hub linking tumor metabolism to CD8+ T cell exhaustion in DLBCL.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Diffuse large B-cell lymphoma (DLBCL) features an immunosuppressive tumor microenvironment (TME), yet the molecular drivers connecting metabolic reprogramming to immune evasion remain poorly defined. Here, we deployed an integrative single-cell transcriptomic analysis combined with a machine learning (ML) framework to systematically identify key immune-suppressive hubs in DLBCL. Through ML-driven prioritization of a 33-gene panel, PAICS emerged as a central node within an immunosuppressive B-cell subgroup. Functional assays confirmed that PAICS promotes lymphoma proliferation, survival, and tumor growth while establishing an immunosuppressive TME-marked by reduced IFN‑γ, elevated TGF‑β and IL‑10, and enhanced CD8⁺ T cell exhaustion. Mechanistically, we uncovered the IRF4-PAICS-LDHA axis: IRF4 transcriptionally activates PAICS, which physically interacts with LDHA to augment its activity, thereby skewing the NAD⁺/NADH balance toward metabolic immunosuppression. Importantly, our AI-aided approach not only identified this axis but also predicted its vulnerability to metabolic intervention: both methotrexate treatment and LDHA knockdown restored metabolic balance, reversed T‑cell exhaustion, and suppressed tumor growth. These findings highlight the power of ML in uncovering multi-targetable metabolic-immune networks and in guiding therapeutic strategies to overcome immune evasion in DLBCL.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.